Similar articles

• [Cyclic GMP (cGMP)].

  Okuya S. Okuya S. Nihon Rinsho. 2005 Aug;63 Suppl 8:615-7. Nihon Rinsho. 2005. PMID: 16149592 Review. Japanese. No abstract available.
• [Cyclic GMP as a biomarker for cardiovascular disease and cancer].

  Ulvestad L, Sager G. Ulvestad L, et al. Tidsskr Nor Laegeforen. 2005 Jan 6;125(1):27-8. Tidsskr Nor Laegeforen. 2005. PMID: 15643459 Review. Norwegian.
• Relationships between circulating ANP, cyclic GMP and sodium excretion in normal human subjects.

  Sagnella GA, Markandu ND, Buckley MG, Singer DR, MacGregor GA. Sagnella GA, et al. J Hum Hypertens. 1993 Apr;7(2):181-2. J Hum Hypertens. 1993. PMID: 8389873 No abstract available.
• [Clinical significance of cyclic GMP assay].

  Kaku K, Harada Y, Kaneko T. Kaku K, et al. Nihon Rinsho. 1990 Feb;48 Suppl:138-40. Nihon Rinsho. 1990. PMID: 2162414 Japanese. No abstract available.
• An enzyme-linked immunosorbent assay (ELISA) for guanosine 3',5'-cyclic monophosphate (cGMP) in human plasma and urine using monoclonal antibody.

  Tsugawa M, Moriwaki K, Iida S, Fujii H, Gomi M, Tarui S, Yamane R, Fujimoto M. Tsugawa M, et al. J Immunoassay. 1991;12(2):263-76. doi: 10.1080/01971529108055071. J Immunoassay. 1991. PMID: 1646221